Combining the checkpoint inhibitor atezolizumab with targeted therapy led to improvements in overall survival in patients with anaplastic thyroid cancer.

Editor's note: This story has been revised to include additional comments. CHICAGO — In patients with stage IVB anaplastic ...

But some patients can present with what’s known as an anaplastic thyroid carcinoma (ATC) — a rare and very aggressive tumor with a very poor prognosis. Now, a clinical trial offers new hope to ...

medullary thyroid cancer, and anaplastic thyroid cancer, with papillary thyroid cancer comprising 84% of cases. Key risk factors include exposure to high levels of radiation, certain inherited ...

But some patients can present with what's known as an anaplastic thyroid carcinoma (ATC) -- a rare and very aggressive tumor with a very poor prognosis. Now, a clinical trial offers new hope to ...

But some patients can present with what's known as an anaplastic thyroid carcinoma (ATC) -- a rare and very aggressive tumor ...

Combining cancer immunotherapy with another treatment ... doctors in Texas report. “Patients with anaplastic thyroid carcinoma need treatments that work fast, and we saw promising results ...

HOUSTON ― Researchers from The University of Texas MD Anderson Cancer Center demonstrated that anti-PD-L1 immunotherapy in combination with mutation-directed targeted therapy extended overall survival ...

Support for the study of anaplastic thyroid carcinoma came from Genentech, the Rare Tumor Initiative, the University of Texas MD Anderson Cancer Center, and NIH. Cabanillas disclosed relationships ...

Anaplastic thyroid carcinoma is a rare and highly aggressive malignant tumor with a very poor prognosis. ATC often develops from differentiated thyroid cancer subtypes, such as papillary and ...

Armour Thyroid (desiccated thyroid) is a brand-name oral tablet prescribed for certain thyroid conditions. As with other drugs, Armour Thyroid can cause side effects, such as temporary hair loss ...